- ABOUT Hematopoietic stem cell transplantation (HSCT)
Hematopoietic stem cell transplantation (HSCT) involves the intravenous (IV)
infusion of autologous or allogeneic stem cells to re-establish hematopoietic function in patients whose bone marrow or immune system is damaged or defective.
There are three kinds of bone marrow transplants, the type Aaron will be having is Autologous. The term auto means self. Stem cells are removed from you before you receive high-dose chemotherapy or radiation treatment. The stem cells are stored in a freezer (cryopreservation). After high-dose chemotherapy or radiation treatments, your stems cells are put back in your body to make (regenerate) normal blood cells. This is called a rescue transplant.
Before the transplant, chemotherapy, radiation, or both may be given. In Russia it would be Non-myeloablative chemotherapy. Non- Myelo is a reduced intensity treatment, also called a mini transplant. Patients receive lower doses of chemotherapy before a transplant. This allows older patients, and those with other health problems to have a transplant.
Dr Fedorenko uses non-myelo on all foreign patients, this treatment has less than 1% mortality risk and Dr Fedorenko has had NO MS deaths in 400+ patients (figures to mid 2014).
The A.A. Maximov Hematology and Cell Therapy Department of the National Pirogov Medical Surgical Centre specializes in the state-of-the-art treatment of hematological, oncological and autoimmune diseases. The accommodation standards and quality of medical care in the Department are at least equal to those of leading American and Western European medical centers.
The A.A. Maximov Hematology and Cell Therapy Department of the National Pirogov Medical Surgical Centre Website – http://msclerosis.ru/eng.php
- STATISTICAL INFORMATION ABOUT HSCT RELATED TO MS
by George Goss (USA) as of FEB/5/2014
As for how many people have undergone HSCT worldwide, it is between one and two million patients since 1967 when it was first established as a successful clinical treatment, most for cancer. HSCT is currently performed 50,000 times per year worldwide, also mainly for cancer. So clearly HSCT is not an “experimental” procedure as it is an extremely well understood medical procedure. As for HSCT for auto immune diseases performed in total today, it is between 2000 and 2500 cumulative with approximately half being for multiple sclerosis. But the number of HSCT-treated autoimmune disease patients increases every year. Eventually (in approximately ten years) HSCT will become an FDA approved treatment for MS.
Overall, ‘approximately’ 85% of the entire MS population, on average, will experience benefit from HSCT. For early relapsing patients it is virtually all.. . . . . “After an average follow-up of three years after receiving their transplants (which took place between January 2003 and February 2005), 17 patients (81 per cent) improved by at least one point on a [EDSS] disability scale. And for all [100%] patients, the disease had stopped progressing.”. . . . .
2013: There are now worldwide trials for MS with this treatment.
About 650 people have had HSCT for MS in the last 12 years… 85% have halted their progression, 14% had no benefit and 1% mortality.
Source: George Goss
For more reading on statistics:
Interesting Statistics from Sweden –
Note: Overall mortality was 0 % & Relapse free survival was 89 %!
Hospitals conducting HSCT for MS
- Heidelberg University Hospital, Germany
- Northwestern University Hospital, USA
- Ottowa General Hospital, Canada
- A.A Maximov Dept. Hematology & Cellular Therapy, Russia.
- International Center for Cell Therapy & Cancer Immunology, Israel
- Manipal Hospital, India